Targeting cap-dependent translation initiation is one of the experimental approaches that could lead to the development of novel anti-cancer therapies. Synthetic dinucleoside 5′,5′-triphosphates cap analogs are potent antagonists of eukaryotic translation initiation factor 4E (eIF4E)in vitroand could counteract elevated levels of eIF4E in cancer cells; however, transformation of these compounds into therapeutic agents remains challenging - they do not easily penetrate into cells and are susceptible to enzymatic cleavage. Here, we tested the potential of several small molecule ligands - folic acid, biotin, glucose, and cholesterol - to deliver both hydrolyzable and cleavage-resistant cap analogs into cells. A broad structure-activity relationship (SAR) study using model fluorescent probes and cap-ligand conjugates showed that cholesterol greatly facilitates uptake of cap analogs without disturbing the interactions with eIF4E. The most potent cholesterol conjugate identified showed apoptosis-mediated cytotoxicity towards cancer cells.
CITATION STYLE
Kleczewska, N., Sikorski, P. J., Warminska, Z., Markiewicz, L., Kasprzyk, R., Baran, N., … Jemielity, J. (2021). Cellular delivery of dinucleotides by conjugation with small molecules: targeting translation initiation for anticancer applications. Chemical Science, 12(30), 10242–10251. https://doi.org/10.1039/d1sc02143e
Mendeley helps you to discover research relevant for your work.